PillaiSMattooHCariappaA. B cells and autoimmunity. Curr Opin Immunol2011; 23: 721–731.
2.
RenaudineauYHillionSSarauxAMageedRAYouinouP. An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood2005; 106: 2781–2789.
3.
YouinouPRenaudineauY. CD5 expression in B cells from patients with systemic lupus erythematosus. Crit Rev Immunol2011; 31: 31–42.
4.
HillionSSarauxAYouinouPJaminC. Expression of RAGs in peripheral B cells outside germinal centers is associated with the expression of CD5. J Immunol2005; 174: 5553–5561.
5.
KasaianMTIkematsuHCasaliP. Identification and analysis of a novel human surface CD5-B lymphocyte subset producing natural antibodies. J Immunol1992; 148: 2690–2702.
6.
ChungJBSilvermanMMonroeJG. Transitional B cells: step by step towards immune competence. Trends Immunol2003; 24: 343–349.
7.
MartinFKearneyJF. Marginal-zone B cells. Nature Rev Immunol2002; 2: 323–335.
8.
Le PottierLDevauchelleVFautrelA. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol2009; 182: 3540–3547.
9.
GuerrierTLe PottierLDevauchelleVPersJOJaminCYouinouP. Role of toll-like receptors in primary Sjogren's syndrome with a special emphasis on B-cell maturation within exocrine tissues. J Autoimmun2012; 39: 69–76.
10.
PascualVLiuYJMagalskiAde BouteillerOBanchereauJCapraJD. Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med1994; 180: 329–339.
11.
MorvaALemoineSAchourAPersJOYouinouPJaminC. Maturation and function of human dendritic cells are regulated by B lymphocytes. Blood2012; 119: 106–114.
12.
LemoineSMorvaAYouinouPJaminC. Human T cells induce their own regulation through activation of B cells. J Autoimmun2011; 36: 228–338.
13.
GaraudSMorvaALemoineS. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol2011; 186: 4835–4844.
14.
BlairPANorenaLYFlores-BorjaF. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity2010; 32: 129–140.
15.
MackayFWoodcockSALawtonP. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med1999; 190: 1697–1710.
16.
Le PottierLBendaoudBRenaudineauYYouinouPPersJODaridonC. New ELISA for B cell-activating factor. Clin Chem2009; 55: 1843–1851.
17.
YouinouPPersJO. The late news on baff in autoimmune diseases. Autoimmun Rev2010; 9: 804–806.
18.
EdwardsJCCambridgeG. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Rev Immunol2006; 6: 394–403.
19.
TackeyELipskyPEIlleiGG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus2004; 13: 339–343.
20.
LoMSTsokosGC. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci2012; 1247: 138–152.
